

Global Nucleic Acids for Molecular Diagnosis Market Analysis and Forecast 2025-2031

<https://marketpublishers.com/r/G26DD8995702EN.html>

Date: February 2025

Pages: 191

Price: US\$ 4,950.00 (Single User License)

ID: G26DD8995702EN

Abstracts

Summary

According to APO Research, The global Nucleic Acids for Molecular Diagnosis market is projected to grow from US\$ million in 2025 to US\$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nucleic Acids for Molecular Diagnosis is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Nucleic Acids for Molecular Diagnosis is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Nucleic Acids for Molecular Diagnosis is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Nucleic Acids for Molecular Diagnosis is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Nucleic Acids for Molecular Diagnosis include Agilent Technologies, Inc., Aji Bio-Pharma, Bio-synthesis Inc., Danaher Corporation, Eurofins Scientific SE, Integrated DNA Technologies, Kaneka Eurogentec S.A., L.G.C Biosearch Technologies and Merck KGaA, etc. In 2024, the world's top three vendors accounted

for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nucleic Acids for Molecular Diagnosis, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Nucleic Acids for Molecular Diagnosis, also provides the revenue of main regions and countries. Of the upcoming market potential for Nucleic Acids for Molecular Diagnosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nucleic Acids for Molecular Diagnosis revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nucleic Acids for Molecular Diagnosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Nucleic Acids for Molecular Diagnosis revenue, projected growth trends, production technology, application and end-user industry.

Nucleic Acids for Molecular Diagnosis Segment by Company

Agilent Technologies, Inc.

Aji Bio-Pharma

Bio-synthesis Inc.

Danaher Corporation

Eurofins Scientific SE

Integrated DNA Technologies

Kaneka Eurogentec S.A.

L.G.C Biosearch Technologies

Merck KGaA

metabion

QIAGEN

Thermo Fisher Scientific Inc.

Hongene

Synthgene

Nucleic Acids for Molecular Diagnosis Segment by Type

DNA Series

RNA Series

Nucleic Acids for Molecular Diagnosis Segment by Application

Early Cancer Screening

Genetic Diseases

Blood Screening

Genome Sequencing

Infectious Diseases

Other

Nucleic Acids for Molecular Diagnosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Turkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Acids for Molecular Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Acids for Molecular Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception

concerning the adoption of Nucleic Acids for Molecular Diagnosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nucleic Acids for Molecular Diagnosis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nucleic Acids for Molecular Diagnosis company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acids for Molecular Diagnosis revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Nucleic Acids for Molecular Diagnosis Market by Type
 - 1.2.1 Global Nucleic Acids for Molecular Diagnosis Market Size by Type, 2020 VS 2024 VS 2031
 - 1.2.2 DNA Series
 - 1.2.3 RNA Series
- 1.3 Nucleic Acids for Molecular Diagnosis Market by Application
 - 1.3.1 Global Nucleic Acids for Molecular Diagnosis Market Size by Application, 2020 VS 2024 VS 2031
 - 1.3.2 Early Cancer Screening
 - 1.3.3 Genetic Diseases
 - 1.3.4 Blood Screening
 - 1.3.5 Genome Sequencing
 - 1.3.6 Infectious Diseases
 - 1.3.7 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

2 NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET DYNAMICS

- 2.1 Nucleic Acids for Molecular Diagnosis Industry Trends
- 2.2 Nucleic Acids for Molecular Diagnosis Industry Drivers
- 2.3 Nucleic Acids for Molecular Diagnosis Industry Opportunities and Challenges
- 2.4 Nucleic Acids for Molecular Diagnosis Industry Restraints

3 GLOBAL GROWTH PERSPECTIVE

- 3.1 Global Nucleic Acids for Molecular Diagnosis Market Perspective (2020-2031)
- 3.2 Global Nucleic Acids for Molecular Diagnosis Growth Trends by Region
 - 3.2.1 Global Nucleic Acids for Molecular Diagnosis Market Size by Region: 2020 VS 2024 VS 2031
 - 3.2.2 Global Nucleic Acids for Molecular Diagnosis Market Size by Region (2020-2025)
 - 3.2.3 Global Nucleic Acids for Molecular Diagnosis Market Size by Region (2026-2031)

4 COMPETITIVE LANDSCAPE BY PLAYERS

4.1 Global Nucleic Acids for Molecular Diagnosis Revenue by Players

4.1.1 Global Nucleic Acids for Molecular Diagnosis Revenue by Players (2020-2025)

4.1.2 Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Players (2020-2025)

4.1.3 Global Nucleic Acids for Molecular Diagnosis Players Revenue Share Top 10 and Top 5 in 2024

4.2 Global Nucleic Acids for Molecular Diagnosis Key Players Ranking, 2023 VS 2024 VS 2025

4.3 Global Nucleic Acids for Molecular Diagnosis Key Players Headquarters & Area Served

4.4 Global Nucleic Acids for Molecular Diagnosis Players, Product Type & Application

4.5 Global Nucleic Acids for Molecular Diagnosis Players Establishment Date

4.6 Market Competitive Analysis

4.6.1 Global Nucleic Acids for Molecular Diagnosis Market CR5 and HHI

4.6.3 2024 Nucleic Acids for Molecular Diagnosis Tier 1, Tier 2, and Tier

5 NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE BY TYPE

5.1 Global Nucleic Acids for Molecular Diagnosis Revenue by Type (2020 VS 2024 VS 2031)

5.2 Global Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2031)

5.3 Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Type (2020-2031)

6 NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE BY APPLICATION

6.1 Global Nucleic Acids for Molecular Diagnosis Revenue by Application (2020 VS 2024 VS 2031)

6.2 Global Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2031)

6.3 Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Application (2020-2031)

7 COMPANY PROFILES

7.1 Agilent Technologies, Inc.

- 7.1.1 Agilent Technologies, Inc. Company Information
- 7.1.2 Agilent Technologies, Inc. Business Overview
- 7.1.3 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 7.1.4 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
- 7.1.5 Agilent Technologies, Inc. Recent Developments
- 7.2 Aji Bio-Pharma
 - 7.2.1 Aji Bio-Pharma Company Information
 - 7.2.2 Aji Bio-Pharma Business Overview
 - 7.2.3 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
 - 7.2.4 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Portfolio
 - 7.2.5 Aji Bio-Pharma Recent Developments
- 7.3 Bio-synthesis Inc.
 - 7.3.1 Bio-synthesis Inc. Company Information
 - 7.3.2 Bio-synthesis Inc. Business Overview
 - 7.3.3 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
 - 7.3.4 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
 - 7.3.5 Bio-synthesis Inc. Recent Developments
- 7.4 Danaher Corporation
 - 7.4.1 Danaher Corporation Company Information
 - 7.4.2 Danaher Corporation Business Overview
 - 7.4.3 Danaher Corporation Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
 - 7.4.4 Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Portfolio
 - 7.4.5 Danaher Corporation Recent Developments
- 7.5 Eurofins Scientific SE
 - 7.5.1 Eurofins Scientific SE Company Information
 - 7.5.2 Eurofins Scientific SE Business Overview
 - 7.5.3 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
 - 7.5.4 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Portfolio
 - 7.5.5 Eurofins Scientific SE Recent Developments
- 7.6 Integrated DNA Technologies
 - 7.6.1 Integrated DNA Technologies Company Information
 - 7.6.2 Integrated DNA Technologies Business Overview
 - 7.6.3 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Revenue

and Gross Margin (2020-2025)

7.6.4 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio

7.6.5 Integrated DNA Technologies Recent Developments

7.7 Kaneka Eurogentec S.A.

7.7.1 Kaneka Eurogentec S.A. Company Information

7.7.2 Kaneka Eurogentec S.A. Business Overview

7.7.3 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)

7.7.4 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Portfolio

7.7.5 Kaneka Eurogentec S.A. Recent Developments

7.8 L.G.C Biosearch Technologies

7.8.1 L.G.C Biosearch Technologies Company Information

7.8.2 L.G.C Biosearch Technologies Business Overview

7.8.3 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)

7.8.4 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio

7.8.5 L.G.C Biosearch Technologies Recent Developments

7.9 Merck KGaA

7.9.1 Merck KGaA Company Information

7.9.2 Merck KGaA Business Overview

7.9.3 Merck KGaA Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)

7.9.4 Merck KGaA Nucleic Acids for Molecular Diagnosis Product Portfolio

7.9.5 Merck KGaA Recent Developments

7.10 metabion

7.10.1 metabion Company Information

7.10.2 metabion Business Overview

7.10.3 metabion Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)

7.10.4 metabion Nucleic Acids for Molecular Diagnosis Product Portfolio

7.10.5 metabion Recent Developments

7.11 QIAGEN

7.11.1 QIAGEN Company Information

7.11.2 QIAGEN Business Overview

7.11.3 QIAGEN Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)

7.11.4 QIAGEN Nucleic Acids for Molecular Diagnosis Product Portfolio

- 7.11.5 QIAGEN Recent Developments
- 7.12 Thermo Fisher Scientific Inc.
 - 7.12.1 Thermo Fisher Scientific Inc. Company Information
 - 7.12.2 Thermo Fisher Scientific Inc. Business Overview
 - 7.12.3 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
 - 7.12.4 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
 - 7.12.5 Thermo Fisher Scientific Inc. Recent Developments
- 7.13 Hongene
 - 7.13.1 Hongene Company Information
 - 7.13.2 Hongene Business Overview
 - 7.13.3 Hongene Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
 - 7.13.4 Hongene Nucleic Acids for Molecular Diagnosis Product Portfolio
 - 7.13.5 Hongene Recent Developments
- 7.14 Synthgene
 - 7.14.1 Synthgene Company Information
 - 7.14.2 Synthgene Business Overview
 - 7.14.3 Synthgene Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
 - 7.14.4 Synthgene Nucleic Acids for Molecular Diagnosis Product Portfolio
 - 7.14.5 Synthgene Recent Developments

8 NORTH AMERICA

- 8.1 North America Nucleic Acids for Molecular Diagnosis Revenue (2020-2031)
- 8.2 North America Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2031)
 - 8.2.1 North America Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2025)
 - 8.2.2 North America Nucleic Acids for Molecular Diagnosis Revenue by Type (2026-2031)
- 8.3 North America Nucleic Acids for Molecular Diagnosis Revenue Share by Type (2020-2031)
- 8.4 North America Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2031)
 - 8.4.1 North America Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2025)
 - 8.4.2 North America Nucleic Acids for Molecular Diagnosis Revenue by Application

(2026-2031)

8.5 North America Nucleic Acids for Molecular Diagnosis Revenue Share by Application (2020-2031)

8.6 North America Nucleic Acids for Molecular Diagnosis Revenue by Country

8.6.1 North America Nucleic Acids for Molecular Diagnosis Revenue by Country (2020 VS 2024 VS 2031)

8.6.2 North America Nucleic Acids for Molecular Diagnosis Revenue by Country (2020-2025)

8.6.3 North America Nucleic Acids for Molecular Diagnosis Revenue by Country (2026-2031)

8.6.4 United States

8.6.5 Canada

8.6.6 Mexico

9 EUROPE

9.1 Europe Nucleic Acids for Molecular Diagnosis Revenue (2020-2031)

9.2 Europe Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2031)

9.2.1 Europe Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2025)

9.2.2 Europe Nucleic Acids for Molecular Diagnosis Revenue by Type (2026-2031)

9.3 Europe Nucleic Acids for Molecular Diagnosis Revenue Share by Type (2020-2031)

9.4 Europe Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2031)

9.4.1 Europe Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2025)

9.4.2 Europe Nucleic Acids for Molecular Diagnosis Revenue by Application (2026-2031)

9.5 Europe Nucleic Acids for Molecular Diagnosis Revenue Share by Application (2020-2031)

9.6 Europe Nucleic Acids for Molecular Diagnosis Revenue by Country

9.6.1 Europe Nucleic Acids for Molecular Diagnosis Revenue by Country (2020 VS 2024 VS 2031)

9.6.2 Europe Nucleic Acids for Molecular Diagnosis Revenue by Country (2020-2025)

9.6.3 Europe Nucleic Acids for Molecular Diagnosis Revenue by Country (2026-2031)

9.6.4 Germany

9.6.5 France

9.6.6 U.K.

9.6.7 Italy

9.6.8 Russia

9.6.9 Spain

- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland

10 CHINA

- 10.1 China Nucleic Acids for Molecular Diagnosis Revenue (2020-2031)
- 10.2 China Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2031)
 - 10.2.1 China Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2025)
 - 10.2.2 China Nucleic Acids for Molecular Diagnosis Revenue by Type (2026-2031)
- 10.3 China Nucleic Acids for Molecular Diagnosis Revenue Share by Type (2020-2031)
- 10.4 China Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2031)
 - 10.4.1 China Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2025)
 - 10.4.2 China Nucleic Acids for Molecular Diagnosis Revenue by Application (2026-2031)
- 10.5 China Nucleic Acids for Molecular Diagnosis Revenue Share by Application (2020-2031)

11 ASIA (EXCLUDING CHINA)

- 11.1 Asia Nucleic Acids for Molecular Diagnosis Revenue (2020-2031)
- 11.2 Asia Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2031)
 - 11.2.1 Asia Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2025)
 - 11.2.2 Asia Nucleic Acids for Molecular Diagnosis Revenue by Type (2026-2031)
- 11.3 Asia Nucleic Acids for Molecular Diagnosis Revenue Share by Type (2020-2031)
- 11.4 Asia Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2031)
 - 11.4.1 Asia Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2025)
 - 11.4.2 Asia Nucleic Acids for Molecular Diagnosis Revenue by Application (2026-2031)
- 11.5 Asia Nucleic Acids for Molecular Diagnosis Revenue Share by Application (2020-2031)
- 11.6 Asia Nucleic Acids for Molecular Diagnosis Revenue by Country
 - 11.6.1 Asia Nucleic Acids for Molecular Diagnosis Revenue by Country (2020 VS 2024 VS 2031)
 - 11.6.2 Asia Nucleic Acids for Molecular Diagnosis Revenue by Country (2020-2025)
 - 11.6.3 Asia Nucleic Acids for Molecular Diagnosis Revenue by Country (2026-2031)

- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia

12 SOUTH AMERICA, MIDDLE EAST AND AFRICA

- 12.1 SAMEA Nucleic Acids for Molecular Diagnosis Revenue (2020-2031)
- 12.2 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2031)
 - 12.2.1 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Type (2020-2025)
 - 12.2.2 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Type (2026-2031)
- 12.3 SAMEA Nucleic Acids for Molecular Diagnosis Revenue Share by Type (2020-2031)
- 12.4 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2031)
 - 12.4.1 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Application (2020-2025)
 - 12.4.2 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Application (2026-2031)
- 12.5 SAMEA Nucleic Acids for Molecular Diagnosis Revenue Share by Application (2020-2031)
- 12.6 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Country
 - 12.6.1 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Country (2020 VS 2024 VS 2031)
 - 12.6.2 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Country (2020-2025)
 - 12.6.3 SAMEA Nucleic Acids for Molecular Diagnosis Revenue by Country (2026-2031)
 - 12.6.4 Brazil
 - 12.6.5 Argentina
 - 12.6.6 Chile
 - 12.6.7 Colombia
 - 12.6.8 Peru
 - 12.6.9 Saudi Arabia
 - 12.6.10 Israel
 - 12.6.11 UAE
 - 12.6.12 Turkey

12.6.13 Iran

12.6.14 Egypt

13 CONCLUDING INSIGHTS

14 APPENDIX

14.1 Reasons for Doing This Study

14.2 Research Methodology

14.3 Research Process

14.4 Authors List of This Report

14.5 Data Source

14.5.1 Secondary Sources

14.5.2 Primary Sources

14.6 Disclaimer

I would like to order

Product name: Global Nucleic Acids for Molecular Diagnosis Market Analysis and Forecast 2025-2031

Product link: <https://marketpublishers.com/r/G26DD8995702EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G26DD8995702EN.html>